T
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
Price:
2 170
ILS
23.65%
Market Cap:
₪1.9B
Income Statement
Earnings Waterfall
Tikun Olam Cannbit Pharmaceuticals Ltd
Tikun Olam Cannbit Pharmaceuticals Ltd
Income Statement
Tikun Olam Cannbit Pharmaceuticals Ltd
Tikun Olam Cannbit Pharmaceuticals Ltd
Currency: ILS
| Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
11
N/A
|
22
+100%
|
28
+29%
|
37
+33%
|
41
+11%
|
49
+20%
|
51
+3%
|
44
-13%
|
43
-4%
|
35
-18%
|
23
-35%
|
|
| Gross Profit | ||||||||||||||
| Cost of Revenue |
0
|
0
|
(6)
|
(21)
|
(30)
|
(44)
|
(52)
|
(46)
|
(44)
|
(44)
|
(48)
|
(36)
|
(19)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
5
N/A
|
1
-90%
|
(2)
N/A
|
(7)
-202%
|
(11)
-51%
|
3
N/A
|
7
+148%
|
(0)
N/A
|
(6)
-3 034%
|
(1)
+79%
|
3
N/A
|
|
| Operating Income | ||||||||||||||
| Operating Expenses |
0
|
(10)
|
(29)
|
(36)
|
(35)
|
(25)
|
(17)
|
(19)
|
(113)
|
(30)
|
(43)
|
(10)
|
(23)
|
|
| Selling, General & Administrative |
0
|
0
|
(15)
|
(25)
|
(29)
|
(21)
|
(24)
|
(19)
|
(25)
|
(21)
|
(19)
|
(12)
|
(9)
|
|
| Research & Development |
0
|
(1)
|
(1)
|
(2)
|
(4)
|
(7)
|
(6)
|
(5)
|
(7)
|
(4)
|
(1)
|
(1)
|
(0)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(4)
|
0
|
(7)
|
0
|
(5)
|
0
|
(2)
|
0
|
(1)
|
0
|
|
| Other Operating Expenses |
0
|
(9)
|
(13)
|
(5)
|
(2)
|
9
|
13
|
10
|
(80)
|
(3)
|
(22)
|
4
|
(14)
|
|
| Operating Income |
0
N/A
|
(10)
N/A
|
(24)
-137%
|
(36)
-52%
|
(38)
-5%
|
(33)
+13%
|
(28)
+14%
|
(16)
+43%
|
(106)
-556%
|
(30)
+72%
|
(49)
-63%
|
(11)
+77%
|
(19)
-74%
|
|
| Pre-Tax Income | ||||||||||||||
| Interest Income Expense |
(3)
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
0
|
(0)
|
(3)
|
(2)
|
(7)
|
(6)
|
|
| Non-Reccuring Items |
0
|
0
|
3
|
2
|
2
|
0
|
2
|
(33)
|
(5)
|
(61)
|
0
|
(22)
|
0
|
|
| Pre-Tax Income |
0
N/A
|
(11)
N/A
|
(21)
-90%
|
(35)
-69%
|
(37)
-7%
|
(34)
+9%
|
(28)
+17%
|
(49)
-74%
|
(111)
-126%
|
(94)
+15%
|
(51)
+46%
|
(40)
+21%
|
(26)
+36%
|
|
| Net Income | ||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
|
| Income from Continuing Operations |
0
|
(11)
|
(21)
|
(35)
|
(37)
|
(34)
|
(28)
|
(49)
|
(111)
|
(94)
|
(51)
|
(40)
|
(26)
|
|
| Income to Minority Interest |
0
|
0
|
1
|
2
|
2
|
1
|
1
|
1
|
4
|
5
|
1
|
0
|
0
|
|
| Net Income (Common) |
0
N/A
|
(11)
N/A
|
(20)
-85%
|
(33)
-63%
|
(35)
-7%
|
(33)
+7%
|
(27)
+17%
|
(48)
-79%
|
(107)
-121%
|
(89)
+17%
|
(50)
+44%
|
(40)
+20%
|
(26)
+36%
|
|
| EPS (Diluted) |
0
N/A
|
-0.58
N/A
|
-0.59
-2%
|
-0.9
-53%
|
-0.86
+4%
|
-0.73
+15%
|
-0.57
+22%
|
-0.95
-67%
|
-1.73
-82%
|
-1.41
+18%
|
-0.99
+30%
|
-0.48
+52%
|
-0.3
+38%
|
|
Switch to:
Switch to:
See Also
Discover More
